The 2023 ESH guidelines for managing hypertension in CKD patients generally agree with the 2021 KDIGO guidelines, reflecting updated evidence-based practices and detailed algorithms.
The 2023 ESH and 2021 KDIGO guidelines largely agree on hypertension management in CKD, with minor differences in treatment algorithms and incorporation of recent evidence.
Until recently, major bodies producing guidelines for the management of hypertension in patients with chronic kidney disease (CKD) disagreed in some key issues. In June 2023, the European Society of Hypertension (ESH) published the new 2023 ESH Guidelines for the management of arterial hypertension a document that was endorsed by the European Renal Association. Several novel recommendations relevant to the management of hypertension in patients with CKD appeared in these guidelines, which have been updated to reflect the latest evidence-based practices in managing hypertension in CKD patients. Most of these are in general agreement with the previous 2021 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines-some reflect different emphasis on some topics (i.e. detailed algorithms on antihypertensive agent use) while others reflect evolution of important evidence in recent years. The aim of the present review is to summarize and comment on key points and main areas of focus in patients with CKD, as well as to compare and highlight the main differences with the 2021 KDIGO Guidelines for the management of blood pressure in CKD.
Theodorakopoulou et al. (Fri,) conducted a review in Hypertension in chronic kidney disease. 2023 ESH Guidelines vs. 2021 KDIGO Guidelines was evaluated. The 2023 ESH guidelines for managing hypertension in CKD patients generally agree with the 2021 KDIGO guidelines, reflecting updated evidence-based practices and detailed algorithms.